TrialClinical lymphoma, myeloma & leukemia2013

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

Jason R Westin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.